Condition: Inoperable Locally Advanced HER2-Negative Breast Cancer · Metastatic HER2-Negative Breast Cancer · Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based on treatment history and tumor characteristics. Each group will receive JSKN016 with chemotherapy or immunotherapy. The goal is to find out how well the treatment works and how safe it is.
This description comes directly from the study's public registry record.
Jian Zhang · +86-21-64175590 · syner2000@126.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06942234